Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
Investigator-led study has commenced dosing
Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors
B...
Continue Reading →
